The clonoSEQ® Watch Registry

Verified

Overview

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

SparkCures ID 1097
Trial Phase Observational Trial
Enrollment 465 Patients
Tags
Trial Sponsors
  • Adaptive Biotechnologies
NCT Identifier

NCT04545333

CLOSED

This trial has terminated.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Patients must be able to provide written informed consent
  2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care
  3. Age ≥ 18 years;
  4. Documented hematologic malignancy (any of the below):
    1. MM
    2. ALL (B and T-cell subtypes)
    3. B-cell NHL (all sub types)
    4. CLL
    5. Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the study:

  1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol
  2. A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers
SparkCures Verified

SparkCures is working closely with Adaptive Biotechnologies to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors